Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $4.2 million.

  • Kiniksa Pharmaceuticals International's Deferred Taxes rose 21615.83% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 14648.95%. This contributed to the annual value of $8.1 million for FY2024, which is 12406.77% up from last year.
  • Kiniksa Pharmaceuticals International's Deferred Taxes amounted to $4.2 million in Q3 2025, which was up 21615.83% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Deferred Taxes peaked at $10.6 million during Q2 2024, and registered a low of -$25.7 million during Q4 2023.
  • Its 5-year average for Deferred Taxes is -$1.2 million, with a median of $1.1 million in 2023.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Deferred Taxes tumbled by 748764.37% in 2023, and later soared by 30529.25% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Deferred Taxes stood at $10000.0 in 2021, then soared by 3380.0% to $348000.0 in 2022, then plummeted by 7487.64% to -$25.7 million in 2023, then skyrocketed by 87.7% to -$3.2 million in 2024, then skyrocketed by 233.64% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, $2.6 million for Q2 2025, and $3.0 million during Q1 2025.